Cargando…
COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318431/ https://www.ncbi.nlm.nih.gov/pubmed/35890060 http://dx.doi.org/10.3390/pathogens11070816 |
_version_ | 1784755289169330176 |
---|---|
author | Sagnelli, Caterina Montella, Laura Grimaldi, Pierantonio Pisaturo, Mariantonietta Alessio, Loredana De Pascalis, Stefania Sagnelli, Evangelista Coppola, Nicola |
author_facet | Sagnelli, Caterina Montella, Laura Grimaldi, Pierantonio Pisaturo, Mariantonietta Alessio, Loredana De Pascalis, Stefania Sagnelli, Evangelista Coppola, Nicola |
author_sort | Sagnelli, Caterina |
collection | PubMed |
description | Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen (HBsAg) chronic carriers. HBV infection may reactivate with symptomatic and sometimes life-threatening clinical manifestations due to a reduction in the immune response of various origins, due to chemotherapy or immunosuppressive therapy, treatments increasingly practiced worldwide. SARS-CoV-2 and its COVID-19 associated disease have introduced new chances for HBV reactivation due to the use of dexamethasone and tocilizumab to counteract the cytokine storm. This could and should be prevented by accurate screening of HBV serologic markers and adequate pharmacologic prophylaxis. This article describes the case of a patient with COVID-19 who developed HBV reactivation and died of liver failure and analyzes published data on this setting to provide useful information to physicians who manage these patients during the SARS-CoV-2 pandemic. |
format | Online Article Text |
id | pubmed-9318431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93184312022-07-27 COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature Sagnelli, Caterina Montella, Laura Grimaldi, Pierantonio Pisaturo, Mariantonietta Alessio, Loredana De Pascalis, Stefania Sagnelli, Evangelista Coppola, Nicola Pathogens Review Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen (HBsAg) chronic carriers. HBV infection may reactivate with symptomatic and sometimes life-threatening clinical manifestations due to a reduction in the immune response of various origins, due to chemotherapy or immunosuppressive therapy, treatments increasingly practiced worldwide. SARS-CoV-2 and its COVID-19 associated disease have introduced new chances for HBV reactivation due to the use of dexamethasone and tocilizumab to counteract the cytokine storm. This could and should be prevented by accurate screening of HBV serologic markers and adequate pharmacologic prophylaxis. This article describes the case of a patient with COVID-19 who developed HBV reactivation and died of liver failure and analyzes published data on this setting to provide useful information to physicians who manage these patients during the SARS-CoV-2 pandemic. MDPI 2022-07-21 /pmc/articles/PMC9318431/ /pubmed/35890060 http://dx.doi.org/10.3390/pathogens11070816 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sagnelli, Caterina Montella, Laura Grimaldi, Pierantonio Pisaturo, Mariantonietta Alessio, Loredana De Pascalis, Stefania Sagnelli, Evangelista Coppola, Nicola COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title | COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title_full | COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title_fullStr | COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title_full_unstemmed | COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title_short | COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature |
title_sort | covid-19 as another trigger for hbv reactivation: clinical case and review of literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318431/ https://www.ncbi.nlm.nih.gov/pubmed/35890060 http://dx.doi.org/10.3390/pathogens11070816 |
work_keys_str_mv | AT sagnellicaterina covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT montellalaura covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT grimaldipierantonio covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT pisaturomariantonietta covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT alessioloredana covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT depascalisstefania covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT sagnellievangelista covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature AT coppolanicola covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature |